Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 77.75
+0.70 (0.91%)
Aug 20, 2026, 4:09 PM HKT
Keymed Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 834.63 | 716.31 | 428.12 | 354.1 | 100.06 | 110.27 | |
Revenue Growth | -4.31% | 67.31% | 20.91% | 253.87% | -9.26% | - |
Cost of Revenue | 174.52 | 89.26 | 12.2 | 36.88 | 2.59 | 17.2 |
Gross Profit | 660.11 | 627.06 | 415.92 | 317.22 | 97.48 | 93.07 |
Selling, General & Admin | 581.3 | 504.2 | 298.83 | 177.01 | 133.91 | 92.45 |
Research & Development | 702.26 | 723.53 | 735.19 | 596.28 | 507.37 | 358.16 |
Other Operating Expenses | 55.24 | 29.78 | 7.99 | 1.36 | 0.68 | 2.96 |
Operating Expenses | 1,339 | 1,258 | 1,042 | 774.65 | 641.97 | 453.57 |
Operating Income | -679.3 | -631.05 | -626.09 | -457.43 | -544.49 | -360.5 |
Interest Expense | -15.82 | -16.91 | -18.46 | -17.26 | -8.4 | -11.13 |
Interest & Investment Income | 70.19 | 70.19 | 88.33 | 88.35 | 54.32 | 7.01 |
Earnings From Equity Investments | -0.51 | -0.67 | -5.26 | -4.75 | -9.71 | -0.72 |
Currency Exchange Gain (Loss) | -31.32 | -31.32 | 18.15 | 11.08 | 139.03 | -54.72 |
Other Non Operating Income (Expenses) | 1,689 | 58.17 | 34.62 | 23.82 | 65.66 | -13.78 |
EBT Excluding Unusual Items | 1,032 | -551.59 | -508.71 | -356.19 | -303.6 | -433.84 |
Gain (Loss) on Sale of Investments | 30.87 | 30.87 | 0.06 | - | - | - |
Other Unusual Items | - | - | - | - | - | -3,459 |
Pretax Income | 1,063 | -520.72 | -508.65 | -356.19 | -303.6 | -3,893 |
Income Tax Expense | 288.89 | 1.87 | 6.26 | 1.6 | - | - |
Earnings From Continuing Operations | 773.82 | -522.6 | -514.91 | -357.79 | -303.6 | -3,893 |
Minority Interest in Earnings | -0.17 | -0.04 | -0.33 | -1.57 | -4.52 | 5.32 |
Net Income | 773.65 | -522.64 | -515.24 | -359.36 | -308.12 | -3,887 |
Net Income to Common | 773.65 | -522.64 | -515.24 | -359.36 | -308.12 | -3,887 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 284 | 274 | 262 | 261 | 261 | 161 |
Shares Outstanding (Diluted) | 286 | 274 | 262 | 261 | 261 | 161 |
Shares Change | 8.53% | 4.59% | 0.22% | 0.09% | 62.34% | 139.72% |
EPS (Basic) | 2.72 | -1.91 | -1.97 | -1.37 | -1.18 | -24.17 |
EPS (Diluted) | 2.71 | -1.91 | -1.97 | -1.37 | -1.18 | -24.17 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -1,046 | -997.55 | -682.11 | -680.76 | -386.42 |
Free Cash Flow Per Share | - | -3.82 | -3.81 | -2.61 | -2.61 | -2.40 |
Gross Margin | 79.09% | 87.54% | 97.15% | 89.59% | 97.42% | 84.40% |
Operating Margin | -81.39% | -88.10% | -146.24% | -129.18% | -544.15% | -326.93% |
Profit Margin | 92.69% | -72.96% | -120.35% | -101.49% | -307.92% | -3525.30% |
Free Cash Flow Margin | - | -146.07% | -233.00% | -192.63% | -680.33% | -350.44% |
EBITDA | -597 | -549.27 | -551.07 | -405.8 | -522.22 | -347.7 |
EBITDA Margin | -71.53% | -76.68% | -128.72% | -114.60% | - | - |
D&A For EBITDA | 82.29 | 81.78 | 75.01 | 51.63 | 22.27 | 12.8 |
EBIT | -679.3 | -631.05 | -626.09 | -457.43 | -544.49 | -360.5 |
EBIT Margin | -81.39% | -88.10% | -146.24% | -129.18% | - | - |